Functional Dyspepsia: The 'Other' Stomach Problem Nobody Talks About

You have probably heard of IBS. You have almost certainly heard of acid reflux. But functional dyspepsia? Most people have never encountered the term, even though it affects somewhere between 10 and 20 percent of the population worldwide (Sperber et al., 2021). It is one of the most common reasons people see a gastroenterologist, and yet it is remarkably under-discussed in the public conversation about digestive health. Functional dyspepsia refers to persistent or recurrent discomfort centered in the upper part of your abdomen, the area just below your ribs and above your belly button, that cannot be explained by a structural or biochemical abnormality on standard testing. Your endoscopy comes back normal. Your blood work is fine. But the symptoms are very real, and for many people, they are genuinely disruptive to daily life.

What exactly is functional dyspepsia, and how is it different from indigestion?

The word dyspepsia literally means 'bad digestion,' and for decades it was used as a catch-all for any upper abdominal discomfort. The problem with that vagueness is that it lumped together people with ulcers, people with gallstones, people with H. pylori infections, and people whose stomachs appeared entirely normal on every test. Modern gastroenterology now draws a clear line. If standard testing reveals a cause, you have organic dyspepsia. If it does not, you have functional dyspepsia. This distinction matters because the treatment approach differs substantially.

The Rome IV criteria, which represent the current international consensus for defining functional GI disorders, require that symptoms be present for at least 3 months with onset at least 6 months before diagnosis. The symptoms must include one or more of the following: bothersome postprandial fullness, early satiation (feeling full too quickly after starting a meal), epigastric pain, or epigastric burning. And these symptoms must not be fully explained by another medical condition (Stanghellini et al., 2016).

The two subtypes: EPS and PDS

One of the most useful advances in understanding functional dyspepsia has been splitting it into two distinct subtypes. This is not just academic classification. It actually influences which treatments are most likely to help you.

Epigastric pain syndrome (EPS) is characterized primarily by pain or burning in the upper abdomen. The discomfort does not have to be related to meals, and it can occur on an empty stomach. Some patients describe it as gnawing or aching. It can look and feel a lot like an ulcer, except there is no ulcer to find. EPS tends to respond somewhat better to acid-suppressing medications and to tricyclic antidepressants.

Postprandial distress syndrome (PDS), on the other hand, centers on meal-related symptoms. The hallmarks are uncomfortable fullness after eating a normal-sized meal and early satiation, meaning you feel unable to finish a meal even when you have only eaten a small amount. Bloating and nausea are common companions. PDS can make eating feel like a chore or even something to dread. This subtype is often linked to impaired gastric accommodation, where the upper stomach fails to relax adequately to receive food, and it may respond better to prokinetics and fundic-relaxing agents (Vanheel et al., 2017).

In practice, many patients have features of both subtypes, and the overlap can make classification tricky. But even an imperfect subtyping gives clinicians a better starting point for treatment than treating all dyspepsia identically.

What causes functional dyspepsia?

This is where things get complicated, because there is probably no single cause. Functional dyspepsia appears to be a disorder where multiple overlapping mechanisms contribute in different proportions for different people. Researchers have identified several contributing factors that, individually or in combination, seem to drive symptoms.

One particularly interesting finding is that functional dyspepsia often begins after an acute gastrointestinal infection. A meta-analysis found that roughly 10 percent of people who develop gastroenteritis go on to develop persistent dyspepsia symptoms (Pike et al., 2013). This post-infectious pathway may involve lingering low-grade inflammation in the duodenum or changes in the local immune response.

How is functional dyspepsia diagnosed?

Functional dyspepsia is a diagnosis of exclusion, which means your doctor needs to rule out other conditions that could explain your symptoms before landing on it. For most patients, this involves an upper endoscopy (EGD) to look for ulcers, erosions, masses, or celiac disease. Blood tests for H. pylori, celiac antibodies, and basic metabolic panels are typically part of the workup as well.

If the endoscopy is normal and alarm features are absent (no unintentional weight loss, no vomiting, no evidence of bleeding, no family history of upper GI cancer), the diagnosis can often be made clinically. In patients over 60 or those with alarm features, additional imaging or testing may be warranted. A gastric emptying study may be considered if gastroparesis is a concern, but it is not required for the diagnosis.

It is worth noting that hearing 'your tests are normal' can be surprisingly distressing when you are dealing with real symptoms. A normal endoscopy does not mean nothing is happening. It means the problem is functional, involving how the stomach and brain communicate, rather than structural. That distinction is not a dismissal. It is a different kind of diagnosis that points toward different treatments.

Evidence-based treatments: what actually works?

Treatment for functional dyspepsia is genuinely multi-layered, and finding what works often involves some trial and error. No single therapy helps everyone, which reflects the multiple underlying mechanisms at play.

Proton pump inhibitors (PPIs) are usually the first-line treatment, especially for EPS. A Cochrane review found that PPIs are modestly effective, with a number needed to treat of about 10, meaning you need to treat 10 patients for 1 to experience significant improvement beyond what a placebo would provide (Pinto-Sanchez et al., 2017). That is a real but modest effect. PPIs seem to work best when acid-related symptoms (burning, pain) are prominent.

H. pylori eradication is recommended for anyone who tests positive. A Cochrane review showed that eradication provides a small but statistically significant benefit, with a number needed to treat of approximately 14 (Moayyedi et al., 2006). The benefit may take 6 to 12 months to become apparent, which is longer than most patients expect.

Low-dose tricyclic antidepressants (TCAs), particularly amitriptyline, have emerged as an important option. The FDTT trial, a large NIH-funded randomized controlled trial, found that amitriptyline at 50 mg per day was significantly better than placebo for functional dyspepsia, particularly for the EPS subtype (Talley et al., 2015). The dose is much lower than what is used for depression. TCAs work here through their effects on visceral pain signaling, not through mood modification.

Prokinetic agents like itopride and acotiamide (available in some countries but not in the U.S.) can help PDS by improving gastric accommodation and emptying. Buspirone, an anti-anxiety medication, has shown benefit for PDS by relaxing the gastric fundus, though evidence is limited to smaller trials (Tack et al., 2012).

Cognitive behavioral therapy (CBT) has demonstrated real efficacy in controlled trials. A study by Orive et al. (2015) found that CBT significantly reduced dyspepsia symptom severity compared to standard medical care alone. This is not about telling patients their symptoms are psychological. CBT works on functional dyspepsia by modifying the brain's processing of visceral signals, reducing hypervigilance to gut sensations, and helping patients manage the anxiety that often amplifies symptoms.

What helps with tracking symptoms and finding patterns?

Because functional dyspepsia treatment is often iterative, keeping a record of what you eat, when symptoms occur, how severe they are, and what you have already tried can be genuinely valuable. Patterns that are invisible week to week can become obvious over a month or two of tracking. Tools like GLP1Gut can help you log meals, symptoms, and treatment responses so you can walk into a gastroenterology appointment with useful data rather than vague recollections.

Tracking is also helpful for subtyping. If you notice your worst days consistently follow meals, that suggests PDS. If discomfort strikes on an empty stomach or wakes you at night, that points more toward EPS. These patterns inform treatment decisions.

Living with functional dyspepsia: what to expect long term

Functional dyspepsia is typically a chronic condition with a waxing and waning course. Some people have periods of months where symptoms are minimal, followed by flares triggered by stress, dietary changes, or illness. Others experience more persistent symptoms that require ongoing management. A population-based study found that about 50 percent of people with functional dyspepsia still reported symptoms after 5 years of follow-up, though severity often decreased over time (Ford et al., 2015).

The good news is that functional dyspepsia does not progress to serious disease. It does not increase your risk of stomach cancer or lead to organ damage. The bad news is that it can significantly affect quality of life, and the medical system often undertreats it because the testing looks 'normal.' If your current treatment approach is not working, advocating for a trial of a different medication class or a referral to a motility specialist is entirely reasonable.